$2.82
-0.06-2.08%
Ult. Agg.: Oct 21, 4:00 PM
$2.83
-0.05-1.74%
SAB Biotherapeutics (SABS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.28 | $-0.21 | $-0.33 | $-0.51 |
| Actual | $-0.28 | $-0.35 | $-0.46 | $-0.21 |
| Surprise | 0.00% | -66.7% | -39.4% | +58.8% |
| Revenue | ||||
| Estimate | — | — | $249998 | $249998 |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | — | — | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.27 | $-0.27 |
| Revenue | ||
| Consensus | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.28 | $-0.28 | 0.00 % |
| Q1 | May 12, 2026 | $-0.35 | $-0.21 | -66.7 % |
| Q4 | Mar 9, 2026 | $-0.46 | $-0.33 | -39.4 % |
| Q3 | Nov 13, 2025 | $-0.21 | $-0.51 | 58.8 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q4 | Mar 9, 2026 | $0 | $250.00K | -100.0 % |
| Q3 | Nov 13, 2025 | $0 | $250.00K | -100.0 % |
| Q2 | Aug 7, 2025 | $0 | $260.00K | -100.0 % |
| Q1 | May 9, 2025 | $0 | $260.00K | -100.0 % |